Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04321473
Other study ID # WE_REMAIN_EBC_19
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date September 30, 2021

Study information

Verified date March 2020
Source G. d'Annunzio University
Contact Marco Zimarino, MD, PhD
Phone +39 3476045261
Email m.zimarino@unich.it
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The slowly accruing evidence on the treatment of patients with left main coronary artery (LMCA) disease drove evolution in guidelines, that currently establish equivalent safety and efficacy for percutaneous coronary intervention (PCI) as compared to surgery, with a class of recommendation that is subjected to the extension and complexity of concomitant coronary artery disease, as assessed by the SYNTAX score.

The severity of LMCA disease, although extremely relevant due to the extent of the supplied myocardium, is often difficult to assess with traditional angiography, due to lack of appropriate angiographic views, absence of a true "reference" segment, interaction with the intubating catheter. Intravascular techniques with either imaging or functional assessment have been variously tested, although with a disturbing rate of discordant results; moreover, they are frequently underused for a number of reasons, including the additional time needed to assess both left anterior descending (LAD) and left circumflex (LCx) arteries, technical challenges, costs and the small risk associated with maneuvering such devices. Fractional flow reserve (FFR) measured from the coronary angiogram (FFRangio) alone recently documented a high diagnostic accuracy compared with pressure-wire derived FFR.

As for the anatomical localization, the majority of LMCA lesions occur at the bifurcation, where PCI results are less favourable. The distal LMCA differs from the other bifurcations in several characteristics: a) a notable mismatch between the LMCA and the left anterior descending (LAD) artery, hampering the selection of an adequately sized stent, b) the presence of a trifurcation, with a large ramus arising from LMCA in about 10% of cases, c) the presence of left or co-dominant circulation, with the LMCA supplying all or nearly all left ventricular myocardium in about 15% of cases.

Therefore, although the European Bifurcation Club (EBC) recommends a provisional side branch approach in most cases of distal LMCA disease, the threshold for placing a second stent in the side branch may be lower in lesions located on LM bifurcation compared with non-LMCA bifurcations. As for double stenting, the evidence is controversial and a consensus is lacking. Moreover, the optimal treatment of patients with LM trifurcations is still undefined.

The aim of this study is therefore to determine the optimal strategy for the treatment of LM bifurcated lesions.


Description:

PCI access site and technique will be left at the operator's discretion, as well as antithrombotic management.

No limitation will be applied for the technique of PCI. As regards data collection and endpoints, Case Report Form (CRF) will be entered on a web-based platform, where study participants will be able to access and retrieve data at any time during study progress.

In-hospital outcomes will be recorded; all patients discharged alive will be followed up with a 30-day, 6-month, and 1-year telephone interview.

On a center-to-center voluntary basis, pre-PCI and post-PCI angiographic images (made blind regarding patients' identity) will be sent to a study angiographic core-lab for Quantitative Angiography Substudy. The images will be processed using a validated quantitative coronary angiography (QCA) Bifurcation software to assess quantitative data describing bifurcation geometry before and after LMCA PCI. In the Quantitative Angiography Substudy, on exploratory bases, FFRangio data reconstructed by angiographic software will be tested against stenosis LMCA lesion severity and LMCA PCI result.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1500
Est. completion date September 30, 2021
Est. primary completion date April 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients =18 years of age with a diagnosis of documented silent ischemia, stable angina, or acute coronary syndrome (ACS).

- PCI with single or multiple drug-eluting stent (DES) for the treatment of lesion located at LMCA bifurcation and defined as a diameter stenosis of =50% by visual estimation.

Exclusion Criteria:

- Patients who cannot give informed consent or have a life expectancy of =12 months;

- Pregnant or nursing mothers. Women of child-bearing age will be asked if they are pregnant or think that they may be pregnant.

- Contraindication or suspected intolerance to anticoagulant (heparin, bivalirudin) or oral antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
PCI on left main
PCI on left main coronary stenosis

Locations

Country Name City State
n/a

Sponsors (21)

Lead Sponsor Collaborator
G. d'Annunzio University Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland, Chiba University, Clinica Di Montevergine, Clinica Mediterranea, Clinical Centre of Serbia, Clinical Hospital Centre Zagreb, Federico II University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Hospital Clínico Universitario de Valladolid, Hospital Pablo Tobón Uribe, Hospital Universitario Reina Sofia de Cordoba, Instituto Dante Pazzanese de Cardiologia, Mount Sinai Hospital, New York, Pauls Stradins Clinical University Hospital, San Raffaele University Hospital, Italy, Université Paris-Sud, University Hospital Monastir, Tunis, University Medical Centre Maribor, VZW Cardiovascular Research Center Aalst

References & Publications (3)

Lassen JF, Holm NR, Banning A, Burzotta F, Lefèvre T, Chieffo A, Hildick-Smith D, Louvard Y, Stankovic G. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention. 2016 May 17;12(1):38-46. doi: 10.4244/EIJV12I1A7. Review. — View Citation

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group . 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. — View Citation

Zimarino M, Briguori C, Amat-Santos IJ, Radico F, Barbato E, Chieffo A, Cirillo P, Costa RA, Erglis A, Gamra H, Gil RJ, Kanic V, Kedev SA, Maddestra N, Nakamura S, Pellicano M, Petrov I, Strozzi M, Tesorio T, Vukcevic V, De Caterina R, Stankovic G; EuroBifurcation Club. Mid-term outcomes after percutaneous interventions in coronary bifurcations. Int J Cardiol. 2019 May 15;283:78-83. doi: 10.1016/j.ijcard.2018.11.139. Epub 2018 Dec 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiac events (MACE) The composite of: death from any cause, myocardial infarction (MI), stent thrombosis (ST), defined as definite, probable or possible following the Academic Research Consortium. 12 months
Secondary Death All-cause death and cardiovascular death 12 months
Secondary MI Myocardial Infarction 12 months
Secondary ST Stent thrombosis (definite, probable or possible) 12 months
Secondary In-hospital MACE Composite of death, MI and ST 12 Months
Secondary Target Vessel Revascularization (TVR) Target Vessel Revascularization 12 Months
Secondary Bleeding The occurrence of major bleeding, as a bleeding defined by the academic research consortium (BARC)- classified as type 3 (a, b or c) or 5 bleeding event 12 Months
See also
  Status Clinical Trial Phase
Completed NCT00069654 - Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease Phase 2
Completed NCT02919124 - Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device N/A
Recruiting NCT02639962 - Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study N/A
Completed NCT02494557 - Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients N/A
Recruiting NCT01466452 - Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery Phase 2
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Completed NCT00368953 - YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus Phase 4
Completed NCT00319449 - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) Phase 4
Completed NCT00091754 - Atherosclerosis, Plaque and CVD in Communities
Completed NCT00069797 - Epidemiology of Coronary Heart Disease in Men Aged 40 and Over N/A
Completed NCT00024596 - Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) N/A
Completed NCT00037245 - Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA N/A
Completed NCT00006502 - Myocardial Perfusion, Risk Factors, and Coronary Calcium N/A
Completed NCT00006407 - Sex Steroid Hormones and Risk of CHD in Women N/A
Withdrawn NCT00006497 - Long-Term Effects of Subclinical CAD on Cardiac Function
Completed NCT00006309 - Pooling of Cohort Studies on Diet & Coronary Disease N/A
Completed NCT00005269 - Family Blood Pressure Program - GENOA
Completed NCT00000508 - Stanford Coronary Risk Intervention Project (SCRIP) Phase 3
Completed NCT00005147 - Epidemiology of Atherosclerosis N/A

External Links